NCT00783341已完成1 期
An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 25 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 主要终点
- Safety as determined by reported adverse events, laboratory test results, and ECGs
研究概览
简要总结
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
GAP-134
Experimental
干预措施: GAP-134 (Drug)
placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Safety as determined by reported adverse events, laboratory test results, and ECGs
时间窗: 3 weeks
次要结局
- Pharmacokinetic parameters(9 days)
研究者
相似试验
已完成
1 期
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) PatientsLeber Hereditary Optic NeuropathyNCT02064569GenSight Biologics19
已完成
1 期
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.GastroparesisNCT00733551GlaxoSmithKline31
撤回
1 期
A Study of Single Ascending Doses of STAR-101 in Healthy ParticipantsHealthy VolunteersNCT04081597Acanthas Pharma Inc
已完成
1 期
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CChronic Hepatitis C InfectionGenotype 1NCT01194037HanAll BioPharma Co., Ltd.30
已完成
1 期
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral HemorrhageIntracerebral Hemorrhage (ICH)NCT02670824AegisCN LLC48